Becton Dickinson (BDX)
Technical, fundamental, and sentiment analysis with recent related videos.
BDX rates Neutral overall. The fundamental read is bearish: the company passes 6 of 9 quality tests on the Piotroski F-Score; balance sheet is in the Grey zone (Altman Z = 2.06); revenue is growing about 5.0% per year; net income is declining about 1.1% per year. The technical picture is bullish: price is 20.0% above the 200-day moving average; 6.0% above the 50-day; the 50/200 relationship is in a Golden cross. Sentiment is bullish (composite 78/100), based on 6 news articles from recent coverage.
Revenue 3-year avg +5.0%. Net income 3-year avg -1.1%.
Price vs 20DMA +4.8%. RSI 63.65. Bollinger state: Inside Bands.
Composite score 78/100 from the AI judge, based on 6 news items, 0 television segments, and 0 videos.
Latest Market Read
Fundamentals are Bearish because revenue has averaged 5.0 percent per year while net income has averaged -1.1 percent per year, so profits are trailing sales. Technical is Bullish: price sits 4.8 percent above the 20-day moving average (the average closing price over the last 20 trading days), the Relative Strength Index (RSI), a momentum reading, is 63.6, and the stock trades inside its Bollinger Bands (a volatility channel). Sentiment is Bullish with a 78 composite (above the 65 Bullish threshold). Those split signals combine to an overall Neutral rating.
Recent news: Coverage is broadly positive, highlighting a multibillion-dollar U.S. manufacturing agreement to produce syringes, needles and consumables, management's execution progress in high-growth units, and analyst upgrades including Zacks' move to strong-buy; the stock has also rallied ~25% over 90 days and ~39.6% over one year. Sources largely agree on improved execution and potential margin upside, while flagging upcoming fiscal Q4 results and clinical milestones as near-term event risks.
Latest Videos
- No qualified videos yet.